SAN MATEO, Calif. – SmartAirLA will use a $250,000 grant from the Blue Shield of California Foundation to help children with asthma manage their conditions with Adherium smart inhalers. In Los Angeles County, asthma is the leading cause of hospitalizations among underserved children. Over one third of low-income children with asthma in the county went to the emergency room or urgent care for asthma treatment in the last year. Through the initiative, SmartAirLA will provide underserved children with asthma with Bluetooth-sensor enabled inhalers from Adherium that will remind them to take their medication and help doctors monitor their medication regimen. The devices will also pinpoint asthmatic hotspots for air pollution mitigation. “This project puts the Internet of Things into the hands of the people who need it the most—underserved children who are literally struggling for breath,” said Peter Long, president and CEO of the Blue Shield of California Foundation, in a statement. “It will help their communities advocate for a healthier environment with a powerful new dataset.”
SEVEN HILLS, Ohio – Anthem Blue Cross and Blue Shield is enabling Ohio consumers enrolled in its Medicare Advantage health plans who have chronic obstructive pulmonary disease to use digital health products offered by Propeller Health. Propeller’s digital medicines for COPD and asthma management consist of sensors that attach to consumers’ existing inhalers. The sensors are paired with a mobile app to automatically track medication use and provide personal feedback and insights that help individuals manage and cope with symptoms. “This collaboration between Anthem and Propeller gives individuals access to connected care technology that will help them more easily manage their COPD to help them have a better quality of life,” said Dr. Linda Hotchkiss, managing medical director of Anthem’s Medicare Advantage Central Region, in a statement. “Anthem will continue to focus on improving consumers’ health care experience by increasing access to high-quality, meaningful solutions.” Anthem’s care management team will also use Propeller’s online provider portal to help understand consumers’ progress in managing their COPD, providing more targeted, personalized care and treatment. Consumers need a history of at least one emergency room visit or hospitalization caused by COPD to be eligible for this program. “We’re excited to partner with Anthem Blue Cross and Blue Shield in Ohio to bring the benefits of digital medicine to Anthem’s consumers who suffer from COPD,” said David Van Sickle, co-founder and CEO of Propeller Health, in a statement.
SAN MATEO, Calif. – Adherium, a provider of a medication adherence digital platform, is making its Hailie smart inhaler available to more than 40,000 patients of Vitalus Health, a provider of pulmonary health care treatments that is focused on managing patient and physician needs. This agreement expands on a commitment announced in May to explore acollaboration and leverage each other’s capabilities to improve health outcomes. The Hailie solution consists of a sensor that attaches to a patient’s asthma or COPD inhaler medication and software, including an app and online web portal, for both patients and clinicians. The sensor tracks medication usage and sends reminders to patients when it is time to take their medication, helping them to monitor and promote adherence as part of a self-management plan. “Since joining forces earlier this year, we’ve seen a clear path toward a stronger relationship and the potential for better patient outcomes,” said Arik Anderson, CEO of Adherium, in a statement. “Our shared objective to improve not only the health care system but also the patient experience, makes this strategic partnership a natural fit.”
DANVILLE, Penn. – Geisinger Medical Center will use Jvion’s artificial intelligence-powered Cognitive Clinical Success Machine to improve chronic obstructive pulmonary disease-related readmissions, as well as avoidable COPD admissions. “The integration of Jvion’s solution is another step in the Institute’s plan to transform health care delivery by improving quality, outcomes and patient experience, while optimizing efficiencies,” said Dr. Karen Murphy, executive vice president, CIO and founding director of the Steele Institute for Healthcare Innovation at Geisinger, in a statement. “Leveraging demonstrated AI, we hope to accelerate our path to preventing patient illness and deterioration, optimizing patient care and improving patient health outcomes. Our goal is to apply the capabilities of the machine to drive significant improvements for some of the largest and most debilitating challenges that we face as healthcare providers.” Jvion’s Cognitive Clinical Success Machine uses Eigen-based technology to ask a series of questions about a patient’s health and risk. For each question, the machine delivers an individual patient’s risk, the clinical and non-clinical factors propelling the risk, and the most effective actions or interventions to mitigate the risk.
‘This opens up channels for patients to get their arms around their disease’
SAN MATEO, Calif. – Adherium recently received clearance from the U.S. Food and Drug Administration to market its smartinhaler sensor technology direct to consumers, paving the way for people with respiratory conditions to purchase the device over the counter, without a prescription.
“This is part of our overall strategy in the U.S.,” said Arik Anderson, CEO of Adherium, which plans to launch the technology here by the end of June.
Adherium’s smartinhaler sensor was developed for use with AstraZeneca’s Symbicort aerosol asthma inhaler. It is installed into a patient’s inhaler to monitor and promote asthma and chronic obstructive pulmonary disease medication as part of a self-management plan, Anderson said.
The smartinhaler sensor records the date and precise time the inhaler is used and automatically transmits that data to an app on the patient’s phone or tablet. It also stores historical data on usage patterns, allowing physicians to review and help make evidence-based decisions.
“Adherence is not just about remembering to take your medication, but also to ensure you’re using it correctly,” said Anderson. “If the physician is not seeing positive results, they can use the data collected by the smartinhaler to dig deeper and see what’s actually going on. For the first time, this device provides the physician with the feedback that goes beyond patient recollection.”
The sensor design also includes three buttons that help patients access the audio/visual reminders, battery monitoring and Bluetooth wireless technology.
Anderson said several clinical studies over the past couple of years have shown that the use of the company’s smartinhaler technology can decrease visits to the emergency room and missed school days by young patients with asthma and COPD.
“They are good statistics, but if you don’t have access to the technology it can be frustrating,” he said.
Direct-to-consumer approval is a key step in Adherium’s journey through the health care system, said Anderson.
“This FDA approval begins to open up channels for patients to get their arms around their disease,” Anderson said. “It’s the beginning of being able to address the $34 billion problem of non-adherence to respiratory medication.”
CAMBRIDGE, England – Owlstone Medical, a diagnostics company developing a breathalyzer for disease, is partnering with AstraZeneca to explore how breath can be used to identify biomarkers to help differentiate between disease phenotypes relevant for asthma and chronic obstructive pulmonary disease. Through the agreement, Owlstone Medical will provide AstraZeneca with access to its breath biopsy services, including the development of classification algorithms to identify breath biomarkers for precision medicine applications across asthma and COPD. “This agreement with AstraZeneca demonstrates our unrivalled expertise in breath biomarkers,” said Billy Boyle, co-founder and CEO of Owlstone Medical, in a statement. “Through our breath biopsy services we are well positioned to assist the AstraZeneca team to explore how breath biopsy can identify novel biomarkers for asthma and COPD and to optimize their application in precision medicine.”
SAN MATEO, Calif. – The U.S. Food and Drug Administration has cleared Adherium’s Smartinhale sensor for over-the-counter sales. The sensor was cleared for use in AstraZeneca’s Symbicort aerosol inhaler to monitor and promote asthma and COPD medication adherence as part of a self-management plan. It automatically records the date and time the inhaler is used and sends the information to an app on the user’s smartphone or tablet. “Over-the-counter sales of our Smartinhaler sensor for the Symbicort aerosol inhaler continues the advancement of our vision for stronger partnerships between patients and physicians by making adherence to personal management plans easier,” said Arik Anderson, CEO of Adherium, in a statement. “We are now well positioned to launch in the U.S., following successes in Europe and Australia.” OTC clearance means that Adherium’s Smartinhaler can now be sold directly to consumers, including through pharmacies and online, without the need for the patient to first obtain a prescription.
ATLANTA – A new collaborative initiative aims to use machine learning to better identify people living with chronic obstructive pulmonary disease who are at risk of exacerbations and hospitalization.
Health care technology company Jvion is collaborating with the COPD Foundation, the Geisinger health system and pharmaceutical company GSK to leverage cognitive machine technology and data for patients with COPD.
“The best way to prevent readmission is to prevent admission in the first place,” said Dr. Paul Simonelli, director of thoracic medicine at Geisinger. “This initiative will help us identify who is sick enough with COPD to be at risk of admission and how we can prevent it.”
The goal of the initiative is to use Jvion’s Cognitive Clinical Success Machine to identify COPD patients currently under the care of Geisinger who are at risk of hospitalization and most likely to benefit from new medications. The CCSM is an advanced artificial intelligence solution built using an Eigen Spheres engine that uses patient mapping to enable a comprehensive patient view that is amplified beyond the risk of an event to the clinical actions that will improve outcomes and drive patient engagement.
The initiative, funded by GSK, is divided into two phases: phase one will target COPD patients who have had an inpatient stay and who are at risk of a readmission within 30 days of their initial discharge; phase two will focus on identifying COPD patients at-risk of an avoidable hospitalization.
“This is a huge win for us,” said Craig Kephart, CEO of the COPD Foundation, who said the organization has had multiple requests over the years from health care providers looking for information on best practices to prevent readmissions and exacerbations, and preserve lung function for people with COPD. “Developing these algorithms will help to personalize treatment a little more.”
ATLANTA – Health care technology company Jvion is collaborating with the COPD Foundation, the Geisinger health system and health care company GSK to leverage cognitive machine technology and data for patients with chronic obstructive pulmonary disease.
The goal of the collaboration is to use Jvion’s Cognitive Clinical Success Machine to identify COPD patients who are currently under the care of Geisinger and who are at risk of hospitalization and most likely to benefit from new medications.
“By combining COPD disease expertise with the exceptional patient care delivered by Geisinger and Jvion’s leading Cognitive Clinical Success Machine, we are positioned to help patients across the nation,” said Craig Kephart, CEO of the COPD Foundation, in a statement. “This work is intended to demonstrate the power of leading edge, cognitive technology and patient care management to halt instances of rising risk and improve COPD patient lives.”
The Cognitive Clinical Success Machine is an advanced artificial intelligence solution built using Eigenspace—an approach that helps solve complex challenges such as quantum mechanics, search and consumer behavior, facial recognition and patient deterioration. It enables a comprehensive patient view that is amplified beyond the risk of an event to the clinical actions that will improve outcomes and drive patient engagement.
The project, funded by GSK, is divided into two phases. Phase one will target COPD patients who have had an inpatient stay and who are at risk of a readmission within 30 days of their initial discharge; phase two will focus on identifying COPD patients at-risk of an avoidable hospitalization.
“This work has the potential to revolutionize how we support COPD patients both inside and outside of the hospital,” said Dr. Paul Simonelli, director of thoracic medicine at Geisinger, in a statement. “We hope to demonstrate how innovation can improve quality, while lowering costs for vulnerable patient populations.”
MADISON, Wis. and ST. LOUIS – Propeller Health and Express Scripts have formed a strategic partnership to provide Propeller’s digital solution to Express Scripts members using inhaler sensors and a mobile app to manage asthma or COPD. Propeller’s digital sensors enable remote monitoring for patients enrolled in Express Scripts’ Pulmonary Care Value Program. “Our vision is to help patients with asthma or COPD understand and proactively manage their condition, allowing them to breathe easier day in and day out,” said Dr. Glen Stettin, senior vice president and chief innovation officer at Express Scripts, in a statement. Using Bluetooth technology, a Propeller digital sensor is attached to a patient’s inhaler and synced to his or her smartphone. The inhaler’s activity trends are reviewed by pulmonary pharmacists within Express Scripts’ Pulmonary Therapeutic Resource Center, and when the Pulmonary TRC sees that a patient is overusing their rescue inhaler or is non-adherent with their controller medication, pulmonary pharmacists engage and perform counseling using patient-specific data. Through the Propeller mobile app, patients with asthma or COPD also can track their symptoms and triggers, monitor daily asthma condition forecasts and receive tips to encourage more effective self-management.